Medpace HoldingsMEDP +1.40%97 EBITDA Margin % is 21.00% as of Mar. 2026, which is 3% above its 10-year median of 20.39. GuruFocus rates MEDP with a GF Score™ of 97/100 and a GF Value™ of $502.56 (Fairly Valued). The stock has 1 warning sign investors should review. Among 204 Medical Diagnostics & Research companies, Medpace Holdings ranks better than 77.45% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medpace Holdings's EBITDA for the
three
months ended in Mar. 2026 was $148 Mil. Medpace Holdings's Revenue for the
three
months ended in Mar. 2026 was $707 Mil. Therefore, Medpace Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 21.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medpace Holdings EBITDA Margin % Related Terms
Medpace Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDP vs RVTY, ICLR, CRL: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (MEDP) has a EBITDA Margin % of 21.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medpace Holdings and its competitors. This is near median its historical median of 20.39. Over the past decade, Medpace Holdings' EBITDA Margin % has ranged from 17.47 to 25.44. According to the industry distribution chart, Medpace Holdings ranks #46 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 22.5%.
Is Medpace Holdings' EBITDA Margin % too high?
Medpace Holdings' current EBITDA Margin % of 21.00% is near median its 10-year median of 20.39. Over the past 10 years, this metric has ranged from a low of 17.47 to a high of 25.44. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Medpace Holdings' value of 21.00% is 303.8% above this industry median. Based on the distribution chart, Medpace Holdings ranks #46 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Medpace Holdings has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' EBITDA Margin % compare to RVTY and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #46 out of 204 companies for EBITDA Margin %. This places Medpace Holdings in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Medpace Holdings' value of 21.00% is 303.8% above this benchmark. Historically, Medpace Holdings' own EBITDA Margin % has ranged from 17.47 to 25.44 over the past decade. While the company's 10-year median is 20.39 vs. the industry median of 5.20, Medpace Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current EBITDA Margin % of 21.00% is 303.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current EBITDA Margin % is 21.00%, which is near median its own 10-year median of 20.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (MEDP) is currently considered Fairly Valued. The stock's GF Value™ is $502.56, compared to a current price of $519.96 — trading 3.5% above its estimated fair value. The current EBITDA Margin % is 21.00%, which is near median its 10-year median of 20.39 and 303.8% above the Medical Diagnostics & Research industry median of 5.20. Medpace Holdings' overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medpace Holdings (MEDP), the current EBITDA Margin % is 21.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of $519.96 is trading 3.5% above its estimated GF Value™ of $502.56.
GuruFocus considers Medpace Holdings to be Fairly Valued.
Key valuation signals for MEDP:
EBITDA Margin %: 21.00% (near median its 10-year median of 20.39)
GF Value™: $502.56 vs. price of $519.96 (3.5% above fair value)
Industry Position: 303.8% above the Medical Diagnostics & Research median (#46 of 204)
No single metric tells the full story. See the MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
97GF Score
Get the complete analysis for MEDP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDP has been successfully added to your 
